ClinicalTrials.gg
CompletedNCT00539981Updated Apr 6, 2022Results posted

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

A Phase 3 interventional study of FluBlok® and Placebo in Influenza, sponsored by Sanofi. Completed at 24 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,648
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing FluBlok in Influenza, Human — none open to participants now, none under way, none of them phase 3. FluBlok · Influenza, Human.

Enrollment
Largest of 11
4,648 · median 606
Started
2007
with 1 other
Phase 3
3 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
1 of 11
Sanofi

Among the 11 studies testing FluBlok in Influenza, Human, this one has the largest enrollment, is one of 2 that started in 2007, is one of 3 in phase 3, and was the 2nd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 11 studies testing FluBlok in Influenza, Human is open now. The open studies under Influenza, Human, anywhere →

Where they have run

About FluBlok

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing FluBlok in Influenza, Human as a file.
02

Study summary

The purpose of this study was to evaluate a single dose of FluBlok in terms of safety, efficacy and effectiveness in prevention of influenza and influenza-like illness and assess clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three different lots of FluBlok in a subset of participants.

Read the detailed description

All currently licensed influenza vaccines in the United States were produced in embryonated hen's eggs. There were several well-recognized disadvantages to the use of eggs as the substrate for influenza vaccine. Eggs required specialized manufacturing facilities and could be difficult to scale up rapidly in response to an emerging need such as a pandemic. It was usually necessary to adapt candidate vaccine viruses for high-yield growth in eggs, a process that could be time consuming, was not always successful, and could select receptor variants that might have suboptimal immunogenicity. In addition, agricultural diseases that affected chicken flocks, and that might be an important issue in a pandemic due to an avian influenza virus strain, could easily disrupt the supply of eggs for vaccine manufacturing. Therefore, development of alternative substrates for influenza vaccine production had been identified as a high-priority objective.

One potential alternative method for production of influenza vaccine was expression of the influenza virus hemagglutinin (HA) using recombinant deoxyribonucleic acid (DNA) techniques. This alternative avoided dependence on eggs and was very efficient because of the high levels of protein expression under the control of the baculovirus polyhedrin promoter.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Influenza
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult aged 18-49 years.
  • Provided prior to any study procedures.
  • Able to comply with all study procedures.
  • Available for follow-up for the duration of the influenza season.
  • Women of must have had a negative urine pregnancy test at the time of randomization and must be willing to use an adequate form of (includes abstinence, condom with spermicide, licensed hormonal contraceptive, intrauterine device [IUD], monogamous relationship with a vasectomized partner) during the course of the study.

Exclusion criteria

Exclusion Criteria:

  • Long-term use of oral , parenteral steroids, or high-dose inhaled steroids (greater than [>] 800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (Nasal and topical steroids were allowed).
  • Presence of high-risk conditions or other characteristics were considered to be indication for influenza vaccination, as defined by the Advisory Committee on Immunization Practices.
  • Acute febrile illness (defined as having a temperature greater than or equal to [>=]100 degrees Fahrenheit) or upper respiratory tract illness within 72 hours of vaccination. Participants with acute febrile illness were rescheduled after fever resolved.
  • Use of experimental vaccines or any influenza vaccine other than FluBlOk after May 31st 2007 for the 2008 Southern Hemisphere or 2007 to 2008 Northern hemisphere epidemic seasons.
  • as a result of an underlying illness or treatment, or used anticancer chemotherapy or radiation therapy within the preceding 36 months.
  • Any diagnosed or treated actively during the past five (5) years, with two (2) exceptions. Participant with any history of lymphoproliferative disorder were excluded. However, participants with a history of localized non-melanotic skin cancer were eligible.
  • Receipt of any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for ) prior to enrollment in this study.
  • Receipt of an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month prior to enrollment in this study, or expected to receive an experimental agent during study period.
  • Receipt of parenteral immunoglobulin or other blood product within the three months prior to study vaccination.
  • Major psychiatric diagnosis including schizophrenia, bipolar disease or other major depression, or any diagnosis of dementia or associated concomitant medications (e.g., Aricept) used for treating dementia.
  • Known active , , or infection.
  • History of alcohol or drug abuse in the last 5 years.
  • Not available for three or more consecutive weeks during flu surveillance period.
  • Any acute or chronic condition that, in the opinion of the investigator, would render vaccination unsafe or interfere with the evaluation of responses or render the participant unable to meet the requirements of the protocol.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
4,648 participants (actual)

Study arms

  • Experimental
    FluBlok (Lots A, B, C)

    Participants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.

    Biological: FluBlok®

  • Placebo comparator
    Placebo

    Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.

    Biological: Placebo

Interventions

  • BiologicalFluBlok®

    Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004

    Also known as: rHA Trivalent Recombinant Hemagglutinin Influenza Vaccine

  • BiologicalPlacebo

    Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Solicited Injection Site (Local) Reactions

    Solicited reaction (reactogenicity event) was an adverse event (AE) that was pre-listed in electronic case report form(eCRF), considered to be related to vaccination and recorded by participant by means of memory aid. Injection sites reaction included pain,bruising,redness,swelling. Pain and bruising:Grade0: didn't have it at all; Grade1: noticed it, but it didn't interfere with usual activities at all; Grade2: had it, and it was bad enough to prevent a significant part of usual activities; Grade3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine, Redness and swelling: participants measured largest diameter of any injection site reaction and grade them from 0 to 3, where Grade0: measured less than(\<)10 milliliters(mm); Grade1: larger than or equal to(\>=) 10mm and \<20mm; Grade 2: \>=20mm and \<50mm; Grade3: \>=50mm. Participants with multiple symptoms in same category were counted once per category using symptom with maximum grade

    Time frame: Within 7 days post vaccination

  2. Number of Participants Reporting Solicited Systemic Reactions

    Solicited reaction (reactogenicity event) was an AE that was pre-listed in eCRF, considered to be related to vaccination recorded by the participant by means of a memory aid between the day of vaccination (Day 0) and Day 7 post vaccination. Systemic events included fever, fatigue, shivering, joint pain, muscle pain, headache, and nausea. Fever: \>=100.4 degree Fahrenheit (ºF) to \<101.1ºF; \>=101.2ºF to \<102.2ºF; \>=102.2ºF; Fatigue, shivering, joint pain, muscle pain, headache and nausea: Grade 0: didn't have it at all; Grade 1: noticed it, but it didn't interfere with usual activities at all; Grade 2: had it, and it was bad enough to prevent a significant part of usual activities; and Grade 3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine. Participants with multiple symptoms in the same category were counted once per category using the symptom with the maximum grade.

    Time frame: Within 7 days post vaccination

  3. Number of Participants Reporting Unsolicited Adverse Events

    An AE was defined as any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study vaccine, whether or not considered to be related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination, ascertained during follow-up visit or telephone contact up to (and including) the Day 28 contact, whether reported spontaneously by the participant or in response to general questions about current or interim health status.

    Time frame: From Day 0 (post-vaccination) through Day 28 post vaccination

  4. Lot Consistency: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Following FluBlok Vaccination

    GMTs of anti-influenza antibodies were measured using a single radial immunodiffusion (SRID) assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\], and B/Malaysia. Titers were expressed in terms of 1/dilution.

    Time frame: Day 28 post vaccination

  5. Percentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI)

    CDC-defined ILI was defined as fever (body temperature \>=100ºF oral accompanied by cough and/or sore throat, on the same day or on consecutive days) due to strains represented in the vaccine.

    Time frame: 14 days post vaccination through and up to 6 months

Secondary outcomes

  1. Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With FluBlok

    Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\] and B/Malaysia. Seroprotection was defined as a post-vaccination HAI antibody titer of \>=1:40.

    Time frame: 28 days post vaccination

  2. Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With FluBlok

    Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\] and B/Malaysia. Seroconversion was defined as a post-vaccination titer of \>=1:40 in participants with undetectable baseline antibody (HI titer = \<1:10) or a \>=4-fold rise in antibody in participants with a baseline titer of \>=1:10, with the achievement of post-vaccination titer of at least 1:40.

    Time frame: 28 days post vaccination

07

Results

Posted Feb 15, 2021

Participant flow

The study was conducted at 24 active centers in the United States from 15-September-2007 to 28-May-2008.

Participant flow — Overall Study
MilestoneFluBlok (Lots A, B, C)Placebo
Started23442304
Completed20492022
Not completed295282
Withdrew: Adverse events (ae)33
Withdrew: Lost to follow-up260251
Withdrew: Withdrew consent2214
Withdrew: Death11
Withdrew: Other reason-unspecified913

Outcome measures

PrimaryNumber of Participants Reporting Solicited Injection Site (Local) Reactions

Solicited reaction (reactogenicity event) was an adverse event (AE) that was pre-listed in electronic case report form(eCRF), considered to be related to vaccination and recorded by participant by means of memory aid. Injection sites reaction included pain,bruising,redness,swelling. Pain and bruising:Grade0: didn't have it at all; Grade1: noticed it, but it didn't interfere with usual activities at all; Grade2: had it, and it was bad enough to prevent a significant part of usual activities; Grade3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine, Redness and swelling: participants measured largest diameter of any injection site reaction and grade them from 0 to 3, where Grade0: measured less than(\<)10 milliliters(mm); Grade1: larger than or equal to(\>=) 10mm and \<20mm; Grade 2: \>=20mm and \<50mm; Grade3: \>=50mm. Participants with multiple symptoms in same category were counted once per category using symptom with maximum grade

Time frame:
Within 7 days post vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Injection Site (Local) Reactions
ParticipantsFluBlok (Lots A, B, C)Placebo
Injection site pain- Grade 014212050
Injection site pain- Grade 1797177
Injection site pain- Grade 2523
Injection site pain- Grade 321
Injection site bruising- Grade 021972172
Injection site bruising- Grade 16857
Injection site bruising- Grade 261
Injection site bruising- Grade 311
Injection site redness- Grade 021812184
Injection site redness- Grade 17240
Injection site redness- Grade 2156
Injection site redness- Grade 341
Injection site swelling- Grade 021952189
Injection site swelling- Grade 15534
Injection site swelling- Grade 2166
Injection site swelling- Grade 362
PrimaryNumber of Participants Reporting Solicited Systemic Reactions

Solicited reaction (reactogenicity event) was an AE that was pre-listed in eCRF, considered to be related to vaccination recorded by the participant by means of a memory aid between the day of vaccination (Day 0) and Day 7 post vaccination. Systemic events included fever, fatigue, shivering, joint pain, muscle pain, headache, and nausea. Fever: \>=100.4 degree Fahrenheit (ºF) to \<101.1ºF; \>=101.2ºF to \<102.2ºF; \>=102.2ºF; Fatigue, shivering, joint pain, muscle pain, headache and nausea: Grade 0: didn't have it at all; Grade 1: noticed it, but it didn't interfere with usual activities at all; Grade 2: had it, and it was bad enough to prevent a significant part of usual activities; and Grade 3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine. Participants with multiple symptoms in the same category were counted once per category using the symptom with the maximum grade.

Time frame:
Within 7 days post vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Systemic Reactions
ParticipantsFluBlok (Lots A, B, C)Placebo
Fever (>=100.4ºF)22382188
Fever (>=100.4 to <101.1ºF)85
Fever (>=101.2 to <102.2ºF)56
Fever (>=102.2ºF)41
Fatigue- Grade 019321898
Fatigue- Grade 1250256
Fatigue- Grade 27866
Fatigue- Grade 31211
Shivering- Grade 022022160
Shivering- Grade 15254
Shivering- Grade 21213
Shivering- Grade 364
Joint pain- Grade 021832148
Joint pain- Grade 16967
Joint pain- Grade 21412
Joint pain- Grade 364
Muscle pain- Grade 020332077
Muscle pain- Grade 1197124
Muscle pain- Grade 23622
Muscle pain- Grade 368
Headache- Grade 019231877
Headache- Grade 1264273
Headache- Grade 27068
Headache- Grade 31513
Nausea- Grade 021432122
Nausea- Grade 19474
Nausea- Grade 22925
Nausea- Grade 3610
PrimaryNumber of Participants Reporting Unsolicited Adverse Events

An AE was defined as any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study vaccine, whether or not considered to be related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination, ascertained during follow-up visit or telephone contact up to (and including) the Day 28 contact, whether reported spontaneously by the participant or in response to general questions about current or interim health status.

Time frame:
From Day 0 (post-vaccination) through Day 28 post vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Unsolicited Adverse Events
ParticipantsFluBlok (Lots A, B, C)Placebo
Number of Participants Reporting Unsolicited Adverse Events6167
PrimaryLot Consistency: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Following FluBlok Vaccination

GMTs of anti-influenza antibodies were measured using a single radial immunodiffusion (SRID) assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\], and B/Malaysia. Titers were expressed in terms of 1/dilution.

Time frame:
Day 28 post vaccination
Reported as:
Geometric mean · Titer (1/dilution)
Lot Consistency: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Following FluBlok Vaccination
Titer (1/dilution)FluBlok: Lot AFluBlok: Lot BFluBlok: Lot C
A/Solomon Islands (H1N1)346.15 (291.96 to 410.41)322.95 (274.80 to 379.55)381.00 (321.79 to 451.10)
A/Wisconsin (H3N2)390.34 (324.83 to 469.06)192.25 (159.59 to 231.59)240.01 (200.14 to 287.82)
B/Malaysia182.10 (151.95 to 218.24)205.95 (174.16 to 243.55)215.34 (179.31 to 258.62)
Statistical analysis
  • FluBlok: Lot A vs FluBlok: Lot B · ANOVA · p = 0.009 (Threshold for significance of p value was 0.05.) · Gmt ratio: 1.07 · 95% CI 0.85 to 1.36
  • FluBlok: Lot A vs FluBlok: Lot C · ANOVA · p = 0.009 (Threshold for significance of p value was 0.05.) · Gmt ratio: 0.91 · 0.91% CI 0.71 to 1.15
  • FluBlok: Lot B vs FluBlok: Lot C · ANOVA · p = 0.009 · Gmt ratio: 0.85 · 95% CI 0.67 to 1.07Threshold for significance of p value was 0.05.
  • FluBlok: Lot A vs FluBlok: Lot B · ANOVA · p = 0.065 (Threshold of significance for p value was 0.05.) · Gmt ratio: 2.03 · 95% CI 1.56 to 2.64
  • FluBlok: Lot A vs FluBlok: Lot C · ANOVA · p = 0.065 · Gmt ratio: 1.63 · 95% CI 1.26 to 2.11Threshold of significance for p value was 0.05.
  • FluBlok: Lot B vs FluBlok: Lot C · ANOVA · p = 0.065 · Gmt ratio: 0.80 · 95% CI 0.62 to 1.04Threshold of significance for p value was 0.05.
  • FluBlok: Lot A vs FluBlok: Lot B · ANOVA · p = 0.011 · Gmt ratio: 0.88 · 95% CI 0.69 to 1.13Threshold of significance for p value was 0.05.
  • FluBlok: Lot A vs FluBlok: Lot C · ANOVA · p = 0.011 · Gmt ratio: 0.85 · 95% CI 0.65 to 1.09Threshold of significance for p value was 0.05.
  • FluBlok: Lot B vs FluBlok: Lot C · ANOVA · p = 0.011 · Gmt ratio: 0.96 · 95% CI 0.75 to 1.23Threshold of significance for p value was 0.05.
PrimaryPercentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI)

CDC-defined ILI was defined as fever (body temperature \>=100ºF oral accompanied by cough and/or sore throat, on the same day or on consecutive days) due to strains represented in the vaccine.

Time frame:
14 days post vaccination through and up to 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI)
percentage of participantsFluBlok (Lots A, B, C)Placebo
Percentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI)0.040.2
Statistical analysis
  • FluBlok (Lots A, B, C) vs Placebo · Relative protective efficacy: 75.4 · 95% CI -148.0 to 99.5
SecondaryPercentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With FluBlok

Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\] and B/Malaysia. Seroprotection was defined as a post-vaccination HAI antibody titer of \>=1:40.

Time frame:
28 days post vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With FluBlok
percentage of participantsFluBlok (Lots A, B, C)
A/Solomon Islands (H1N1)99 (97.1 to 99.5)
A/Wisconsin (H3N2)97 (94.8 to 98.3)
B/Malaysia96 (94.0 to 97.8)
SecondaryPercentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With FluBlok

Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \[H1N1\], A/Wisconsin \[H3N2\] and B/Malaysia. Seroconversion was defined as a post-vaccination titer of \>=1:40 in participants with undetectable baseline antibody (HI titer = \<1:10) or a \>=4-fold rise in antibody in participants with a baseline titer of \>=1:10, with the achievement of post-vaccination titer of at least 1:40.

Time frame:
28 days post vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With FluBlok
percentage of participantsFluBlok (Lots A, B, C)
A/Solomon Islands (H1N1)78 (73.5 to 81.5)
A/Wisconsin (H3N2)81 (77.1 to 84.6)
B/Malaysia52 (47.0 to 56.5)

Adverse events

Collected over Unsolicited non-serious AEs: Day 0 to Day 28 post vaccination, Solicited reactions: within 7 days post vaccination, SAE: through the end of influenza season (up to 6 months). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FluBlok (Lots A, B, C)1/2,344 (0%)30/2,344 (1.3%)152/2,344 (6.5%)
Placebo1/2,304 (0%)34/2,304 (1.5%)120/2,304 (5.2%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventFluBlok (Lots A, B, C)Placebo
DepressionPsychiatric disorders0/23443/2304
AppendicitisInfections and infestations1/23442/2304
Kidney infectionInfections and infestations0/23442/2304
DehydrationMetabolism and nutrition disorders0/23442/2304
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/23442/2304
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/23440/2304
Suicide attemptPsychiatric disorders2/23441/2304
LymphadenopathyBlood and lymphatic system disorders0/23441/2304
Myocardial infarctionCardiac disorders0/23441/2304
Supraventricular tachycardiaCardiac disorders0/23441/2304
Most frequent other events
Most frequent other events
EventFluBlok (Lots A, B, C)Placebo
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders42/234449/2304
CoughRespiratory, thoracic and mediastinal disorders48/234437/2304
HeadacheNervous system disorders35/234442/2304
Nasal congestionRespiratory, thoracic and mediastinal disorders37/234431/2304

Baseline characteristics

Analysis performed on safety population that included participants who received study vaccine, according to the treatment (FluBlok or Placebo) actually received.

Age, Categorical
Age, Categorical(Participants)FluBlok (Lots A, B, C)PlaceboTotal
<=18 years000
Between 18 and 65 years234423044648
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)FluBlok (Lots A, B, C)PlaceboTotal
Female139113492740
Male9539551908
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FluBlok (Lots A, B, C)PlaceboTotal
Race/Ethnicity — White/Caucasian157015303100
Race/Ethnicity — Black/African-American430447877
Race/Ethnicity — Latino/Hispanic250239489
Race/Ethnicity — Asian6252114
Race/Ethnicity — American Indian/Alaska Native7916
Race/Ethnicity — Native Hawaiian/Pacific Islander6814
Race/Ethnicity — Other-unspecified191938
08

Study locations

24 sites
  • Impact Clinical Trials
    Beverly Hills, California 90211, United States
  • Benchmark Research - Sacramento
    Sacramento, California 95816, United States
  • Benchmark Research - San Francisco
    San Francisco, California 94102, United States
  • University Clinical Research, Inc
    Pembroke Pines, Florida 33024, United States
  • Vince and Associates
    Overland Park, Kansas 66212, United States
  • Kentucky pediatric /Adult Research
    Bardstown, Kentucky 40004, United States
  • Benchmarch Research - New Orleans
    Metairie, Louisiana 70006, United States
  • University of Maryland - Baltimore
    Baltimore, Maryland 21201, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68134, United States
  • Regional Clinical Research, Inc.
    Endwell, New York 13760, United States
  • Rochester Medical Center
    Rochester, New York 14642, United States
  • Carolina Medical Trials
    Winston-Salem, North Carolina 27103, United States
  • Sterling Research
    Cincinnati, Ohio 45246, United States
  • Primary Physicians Research - Pediatric Alliance St. Clair
    Pittsburgh, Pennsylvania 15241, United States
  • Primary Physicians Research
    Pittsburgh, Pennsylvania 15241, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Benchmarch Research - Austin
    Austin, Texas 78705, United States
  • Benchmark Research - Fort Worth
    Fort Worth, Texas 76135, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Benchmark Research - San Angelo
    San Angelo, Texas 76904, United States
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Marshfield Clinic
    Marshfield, Wisconsin 54449, United States
09

References and documents

Publications

  • Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13;29(44):7733-9. doi: 10.1016/j.vaccine.2011.07.128. Epub 2011 Aug 9. PubMed 21835220 ↗
  • Rajendran M, Nachbagauer R, Ermler ME, Bunduc P, Amanat F, Izikson R, Cox M, Palese P, Eichelberger M, Krammer F. Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin. mBio. 2017 Mar 21;8(2):e02281-16. doi: 10.1128/mBio.02281-16. PubMed 28325769 ↗
  • Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. mBio. 2016 Jan 19;7(1):e01996-15. doi: 10.1128/mBio.01996-15. PubMed 26787832 ↗

Related links

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2007 to primary completion in May 2008, 8 months.

Results were first posted in Feb 2021, 12 years 8 months after primary completion. A results delay was requested in Apr 2011.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 8 months is close to that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2007
First posted
Oct 5, 2007
StartActual
Sep 15, 2007
Primary completionActual
May 28, 2008
CompletionActual
May 28, 2008
Results delay requested
Apr 28, 2011
Results first posted
Feb 15, 2021
Last update
Apr 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00539981
Lead sponsor
Sanofi
Collaborators
Protein Sciences Corporation
Responsible party
Sponsor
First posted
Oct 5, 2007
Start date
Sep 15, 2007
Primary completion
May 28, 2008
Completion
May 28, 2008
Results posted
Feb 15, 2021
Last update
Apr 6, 2022

Study contacts

John J Treanor, MD
principal investigator · University of Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluBlok

Start the discussion